Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    BIIB033 | Biogen [Lead] | Phase 1
Show Display Options
Rank Status Study
1 Completed BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
Condition: Healthy
Interventions: Drug: BIIB033;   Drug: Placebo
2 Active, not recruiting Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
Conditions: Multiple Sclerosis;   Acute Optic Neuritis
Intervention: Drug: BIIB033 (opicinumab)
3 Completed Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BIIB033;   Drug: Placebo
4 Active, not recruiting Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
Conditions: Central Nervous System (CNS) Demyelinating Disease;   Multiple Sclerosis
Interventions: Biological: BIIB033;   Other: Placebo

Indicates status has not been verified in more than two years